Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 8;10(2):170.
doi: 10.3390/antibiotics10020170.

Ceftobiprole Perspective: Current and Potential Future Indications

Tommaso Lupia  1 , Carlo Pallotto  2 , Silvia Corcione  3   4 , Lucio Boglione  5 , Francesco Giuseppe De Rosa  1   3
Affiliations
Review

Ceftobiprole Perspective: Current and Potential Future Indications

Tommaso Lupia et al. Antibiotics (Basel). .

Abstract

Ceftobiprole combines an excellent spectrum for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) pathogens, with a low/medium MDR risk, and the β-lactams' safety in frail patients admitted to the hospital in internal medicine wards which may be at high risk of adverse events by anti-MRSA coverage as oxazolidinones or glycopeptides. We aimed to report the available evidence regarding ceftobiprole use in pneumonia and invasive bacterial infections, shedding light on ceftobiprole stewardship. The clinical application and real-life experiences of using ceftobiprole for bloodstream infections, including infective endocarditis, are limited but nevertheless promising. In addition, extended-spectrum ceftobiprole activity, including Enterococcus faecalis, Enterobacteriaceae, and Pseudomonas aeruginosa, has theoretical advantages for use as empirical therapy in bacteremia potentially caused by a broad spectrum of microorganisms, such as catheter-related bacteremia. In the future, the desirable approach to sepsis and severe infections will be administered to patients according to their clinical situation, the intrinsic host characteristics, the susceptibility profile, and local epidemiology, while the "universal antibiotic strategy" will no longer be adequate.

Keywords: bloodstream infections; ceftobiprole; cephalosporin; pneumonia; stewardship.

PubMed Disclaimer

Conflict of interest statement

Outside of the present work, FDR has participated as a Speaker or in Advisory Boards for Correvio, Basilea, Hikma, and Avir Pharma. The other authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Ceftobiprole stewardship perspective: sparing vs. sparring. Abbreviations: CAP—community-acquired pneumonia; MRSA—methicillin-resistant Staphylococcus aureus; PA—Pseudomonas aeruginosa; HAP—hospital-acquired pneumonia; CLABSI—central-line associated bloodstream infections; BL/BLI—β-lactams/β-lactam inhibitor; SSTIs—skin and soft tissue infections.
Figure 2
Figure 2
Literature narrative review flowchart.
See this image and copyright information in PMC

References

    1. Nicholson S.C., Welte T., File T.M., Jr., Strauss R.S., Michiels B., Kaul P., Balis D., Arbit D., Amsler K., Noel G.J. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int. J. Antimicrob. Agents. 2012;39:240–246. doi: 10.1016/j.ijantimicag.2011.11.005. - DOI - PubMed
    1. Awad S.S., Rodriguez A.H., Chuang Y.C., Marjanek Z., Pareigis A.J., Reis G., Scheeren T.W.L., Sánchez A.S., Zhou X., Saulay M., et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril vs. ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin. Infect. Dis. 2014;59:51–61. doi: 10.1093/cid/ciu219. - DOI - PMC - PubMed
    1. Noel G.J., Bush K., Bagchi P., Ianus J., Strauss R.S. A randomized, doubleblind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 2008;46:647–655. doi: 10.1086/526527. - DOI - PubMed
    1. Noel G.J., Strauss R.S., Amsler K., Heep M., Pypstra R., Solomkin J.S. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob. Agents Chemother. 2008;52:37–44. doi: 10.1128/AAC.00551-07. - DOI - PMC - PubMed
    1. Giacobbe D.R., De Rosa F.G., Del Bono V., Grossi P.A., Pea F., Petrosillo N., Rossolini G.M., Tascini C., Tumbarello M., Viale P., et al. Ceftobiprole: Drug evaluation and place in therapy. Expert Rev. Anti. Infect. Ther. 2019;17:689–698. doi: 10.1080/14787210.2019.1667229. - DOI - PubMed

LinkOut - more resources